Last reviewed · How we verify
CE/MPA
CE/MPA is a combined oral contraceptive containing conjugated estrogens and medroxyprogesterone acetate that prevents ovulation and alters the uterine environment to inhibit pregnancy.
CE/MPA is a combined oral contraceptive containing conjugated estrogens and medroxyprogesterone acetate that prevents ovulation and alters the uterine environment to inhibit pregnancy. Used for Contraception, Menstrual cycle regulation.
At a glance
| Generic name | CE/MPA |
|---|---|
| Also known as | Premarin, Provera |
| Sponsor | Organon and Co |
| Drug class | Oral contraceptive (combined estrogen-progestin) |
| Target | Estrogen receptors (ER-α, ER-β) and progesterone receptors (PR-A, PR-B) |
| Modality | Small molecule |
| Therapeutic area | Contraception / Women's Health |
| Phase | Phase 3 |
Mechanism of action
The estrogen component suppresses follicle-stimulating hormone (FSH) and luteinizing hormone (LH), preventing ovarian follicle development and ovulation. The progestin component further inhibits LH surge, thickens cervical mucus to impede sperm transport, and alters the endometrium to prevent implantation. Together these mechanisms provide contraceptive efficacy.
Approved indications
- Contraception
- Menstrual cycle regulation
Common side effects
- Nausea
- Headache
- Breast tenderness
- Breakthrough bleeding
- Venous thromboembolism
Key clinical trials
- Doxycycline and Progestin Therapy for Chronic Endometritis(CE) in Patients With Recurrent Reproductive Failure(RRF) (NA)
- Blinding and Adverse Effects of Ultrasonic Vagus Nerve Stimulation (U-VNS) in Tinnitus (NA)
- Blinding and Adverse Effects of Ultrasonic Vagus Nerve Stimulation (U-VNS) (PHASE1, PHASE2)
- Suction Based Characterization of Healthy and Diseased Skin (NA)
- Tibolone Endometrium Study (Study 32972)(P06470) (PHASE3)
- Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CE/MPA CI brief — competitive landscape report
- CE/MPA updates RSS · CI watch RSS
- Organon and Co portfolio CI